As of the latest Form 4 filed Jul 9, 2026.
What Serina Therapeutics Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 18 most recent filings for SER.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-09 | 2026-07-07 | Brannan Stephen K. Director | PPurchase | +1.00K | $2.03 | $2.03K | No | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Venkatesan Jay Director | CConvert | +224K | $2.25 | $504K | No | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Bailey Gregory Director | CConvert | +6.67M | $2.25 | $15.0M | No | Form 4 ↗ |
| 2026-06-22 | 2026-06-17 | Bailey Gregory, Director | CConvert | +1.77M | $2.25 | $3.98M | No | Form 4 ↗ |
| 2026-06-22 | 2026-05-22 | Venkatesan Jay Director | PPurchase | +589.00 | $1.78 | $1.05K | No | Form 4 ↗ |
| 2026-06-15 | 2026-06-12 | WILSON KAREN J Director | PPurchase | +5.00K | $1.77 | $8.85K | No | Form 4 ↗ |
| 2026-06-15 | 2026-06-11 | WILSON KAREN J, Director | PPurchase | +5.10K | $1.75 | $8.90K | No | Form 4 ↗ |
| 2026-05-27 | 2026-05-26 | LEDGER STEVEN A Chief Executive Officer | AAward | +10.1K | $1.93 | $19.5K | No | Form 4 ↗ |
| 2026-04-21 | 2026-03-31 | Venkatesan Jay Director | AAward | +7.55K | $1.94 | $14.7K | No | Form 4 ↗ |
| 2026-04-21 | 2026-03-31 | Bailey Gregory Director | AAward | +59.7K | $1.94 | $116K | No | Form 4 ↗ |
| 2026-03-24 | 2026-03-23 | Moreadith Randall Chief Scientific Officer | SSale | −6.50K | $2.86 | $18.6K | Yes (planned) | Form 4 ↗ |
| 2026-03-24 | 2026-03-23 | Moreadith Randall, Chief Scientific Officer | MExercise | +6.50K | $0.06 | $390.00 | Yes (planned) | Form 4 ↗ |
| 2026-03-20 | 2026-03-19 | Moreadith Randall Chief Scientific Officer | SSale | −39.0K | $2.50 | $97.5K | Yes (planned) | Form 4 ↗ |
| 2026-03-20 | 2026-03-19 | Moreadith Randall, Chief Scientific Officer | MExercise | +39.0K | $0.06 | $2.34K | Yes (planned) | Form 4 ↗ |
| 2026-01-29 | 2026-01-28 | Moreadith Randall Chief Scientific Officer | SSale | −6.50K | $3.57 | $23.2K | Yes (planned) | Form 4 ↗ |
| 2026-01-29 | 2026-01-28 | Moreadith Randall, Chief Scientific Officer | MExercise | +6.50K | $0.06 | $390.00 | Yes (planned) | Form 4 ↗ |
| 2026-01-23 | 2026-01-22 | Moreadith Randall Chief Scientific Officer | SSale | −2.50K | $2.95 | $7.38K | Yes (planned) | Form 4 ↗ |
| 2026-01-23 | 2026-01-22 | Moreadith Randall, Chief Scientific Officer | MExercise | +2.50K | $0.06 | $150.00 | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also SER’s full analysis or the market-wide insider trading feed. The tabs above jump to SER’s other SEC data.
Source: SEC Form 4 filings for SER, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.